UNSPSC 51112205: Methotrexate/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN300. This VA Drug Class (AN300) classifies this compound as belonging to the group ANTINEOPLASTICS, ANTIMETABOLITES.

UNSPSC 51112205 Methotrexate/sodium chloride, a Commodity code, covers the procurement of methotrexate formulated with sodium chloride — a chemotherapy and immunosuppressant medication supplied as an injectable solution for use in hospitals, clinics, and healthcare systems. State and local healthcare agencies, including county health departments, municipal hospitals, and regional medical authorities, solicit this pharmaceutical under the code to stock inpatient and outpatient oncology and rheumatology treatment programs. Procurement typically occurs through RFQ or standing-order vehicles tied to group purchasing organizations or state pharmaceutical contracts, with orders sized to match patient census, treatment protocols, and inventory management cycles across the healthcare network.

The source provides no recent state and local contract opportunities posted under this code. Without posted solicitations, geographic concentration and issuing-body patterns cannot be characterized reliably. Healthcare procurement for specific pharmaceutical formulations like methotrexate/sodium chloride often flows through established GPO frameworks and state-negotiated pharmaceutical schedules rather than discrete open solicitations, which may account for limited visibility in public RFP/RFQ channels. Firms pursuing this code should monitor state health department purchasing announcements, regional hospital system RFQs, and cooperative purchasing vehicle updates tied to oncology and rheumatology pharmaceutical categories.